Galantamine is a cognitive enhancer that is used to improve mental acuity and promote relaxation.
It is often taken as a lucid dreaming aid and to make it easier to fall asleep after a stressful or anxiety-filled day.
We all can benefit from the deeper sleep that Galantamine provides, since this is the time when our body repairs and restores itself.
Sleep also has a profound effect on memory as it is during the state of REM when memory consolidation occurs.
There are a number of additional nootropic and clinical purposes for taking Galantamine Hydrobromide supplements. Continue reading the information below to learn exactly what this supplement is, how it might help you, and the best ways to use Galantamine powder or tablets.



- Inhibits acetylcholinesterase enzyme in the brain
- Improves memory & mental performance
- Boosts concentration & brain cell health
What Is Galantamine:
Related Topics
This supplement is an alkaloid that comes from the flowers of a plant named Galanthus Causasius.
It can also be created synthetically, and was first developed and studied in the Soviet Union and Eastern Europe back in the 1950’s.
Throughout Europe, this supplement has been used for treating a number of conditions like myasthenia, myopathy, and sensory or motor dysfunctions.
It is also a very popular Nootropic supplement for its benefits upon memory, learning, and general cognition. In the US, this drug has also been approved as a treatment for Alzheimer’s disease by the FDA.
How It Works
There are thought to be two important methods of action for Galantamine.
The first of these is by inhibiting the actions of Acetylcholinesterase. This is an enzyme that goes around the brain seeking to destroy used Acetylcholine molecules within the nerve synapses while new ones are being made for the next nerve impulse. With this enzyme having less effect, this serves to increase the amount of circulating Acetylcholine within the brain.
The second way in which this supplement is thought to work is by binding itself to Acetylcholine receptor sites. This helps to make them even more receptive to the neurotransmitter in question.
So, basically, this supplement helps to increase the level of Acetylcholine activity by working on both sides of the equation. This makes Galantamine similar to the Racetam class of supplements like Piracetam, Aniracetam, Pramiracetam or Oxiracetam.
You can enhance the effects of this compound by using Galantamine in a nootropic stack with other Cholinergics like Alpha GPC or Citicoline.
There are also researchers who think that Galantamine is able to facilitate the release of other neurotransmitters. This would include adrenaline and noradrenaline (epinephrine and norepinephrine). This may be due to a very technical method which involves blocking potassium ion channels in your neurons.
Once the levels of these neurotransmitters are increased in the brain, this leads to a whole host of benefits related to intellectual abilities and energy. These are important effects to everyone seeking improved cognition and even an improved ability to deal with anxiety and stress.
Nootropic Benefits
Due to the enhanced levels of Acetylcholine, Galantamine is responsible for a number of Nootropic benefits.
This includes better memory formation and neuroplasticity or synaptic plasticity. In other words, your brain becomes more adaptable and can respond better to new stimuli and learn with greater ease.
There is also evidence to suggest an improved speed of memory recall is also associated with this supplement. A number of users indicate that supplementation has also led to an increased attention span, improved concentration, and focus. Decision making may also be improved.
Sleep is also enhanced by this supplement. Users are able to relax more quickly and effectively. This leads not only being able to fall asleep quicker (along with lower levels of stress and anxiety) but also to sleeping deeper and waking more refreshed. This is also a popular supplement to help achieve what is known as lucid dreaming or out-of-body experiences.
Galantamine has officially been approved by the FDA for treating Alzheimer’s disease. There is additional evidence to support the contention that it might be effective in treating things like ADD/ADHD, age-related cognitive decline, and other forms of dementia.
Side Effects
Despite this supplement being very safe and well-tolerated there have been some side effects associated with it.
These are normally very mild (and it is rare to see any side effects at all) and include loss of appetite, nausea, tiredness, dizziness, and headaches.
On occasion, people can develop allergic reactions to Galantamine supplements like rashes, hives, bloody or black stools, and swelling of the mouth, lips, or tongue.
If any of these serious reactions occur stop taking the supplement and seek immediate medical attention.
How to Use
This is a relatively powerful nootropic supplement so not much is needed. The general recommendation for Galantamine dosages is anywhere from between 4 and 12 mg taken twice a day. Do not exceed 24 mg in a single day.
You can buy this supplement from several online pharmacies based out of countries such as the UK. You should ideally consult with your doctor before using this supplement so you can ensure that you are healthy enough to take it.
It is also not a good idea to combine this nootropic with other stimulants or to take it with supplements like Huperzine A that are also cholinesterase inhibitors.
- Vossel S, Bauer M, Mathys C, Adams RA, Dolan RJ, Stephan KE, Friston KJ. Cholinergic stimulation enhances Bayesian belief updating in the deployment of spatial attention. J Neurosci. 2014
- Bogaisky M. Galantamine versus risperidone treatment of neuropsychiatric symptoms in patients with probable dementia: an open randomized trial. Am J Geriatr Psychiatry. 2014
- Freund-Levi Y, Bloniecki V, Auestad B, Tysen Bäckström AC, Lärksäter M, Aarsland D. Galantamine versus risperidone for agitation in people with dementia: a randomized, twelve-week, single-center study. Dement Geriatr Cogn Disord. 2014
- Caramelli P, Laks J, Palmini AL, Nitrini R, Chaves ML, Forlenza OV, Vale Fde A, Barbosa MT, Bottino CM, Machado JC, Charchat-Fichman H, Lawson FL. Effects of galantamine and galantamine combined with nimodipine on cognitive speed and quality of life in mixed dementia: a 24-week, randomized, placebo-controlled exploratory trial (the REMIX study). Arq Neuropsiquiatr. 2014
- Koola MM, Buchanan RW, Pillai A, Aitchison KJ, Weinberger DR, Aaronson ST, Dickerson FB. Potential role of the combination of galantamine and memantine to improve cognition in schizophrenia. Schizophr Res. 2014
- Tan CC, Yu JT, Wang HF, Tan MS, Meng XF, Wang C, Jiang T, Zhu XC, Tan L. Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. J Alzheimers Dis. 2014
- Song J, Ahn IS, Kang HS, Myung W, Lee Y, Woo SY, Ku HM, Hwang TY, Carroll BJ, Kim DK. Cognitive subdomain responses to galantamine in Alzheimer's disease. J Nerv Ment Dis. 2014
- Richarz U, Gaudig M, Rettig K, Schauble B. Galantamine treatment in outpatients with mild Alzheimer's disease. Acta Neurol Scand. 2014
- Ohnishi T, Sakiyama Y, Okuri Y, Kimura Y, Sugiyama N, Saito T, Takahashi M, Kobayashi T. The prediction of response to galantamine treatment in patients with mild to moderate Alzheimer's disease. Curr Alzheimer Res. 2014
- [No authors listed] Drugs for cognitive loss and dementia. Treat Guidel Med Lett. 2013
- Freund-Levi Y, Jedenius E, Tysen-Bäckström AC, Lärksäter M, Wahlund LO, Eriksdotter M. Galantamine versus risperidone treatment of neuropsychiatric symptoms in patients with probable dementia: an open randomized trial. Am J Geriatr Psychiatry. 2014
- Tsvetkova D, Obreshkova D, Zheleva-Dimitrova D, Saso L. Antioxidant activity of galantamine and some of its derivatives. Curr Med Chem. 2013
- Isik AT, Bozoglu E, Kaptan K, Celik T. Effect of galantamine on platelet functions in healthy elderly people. Indian J Med Res. 2013
- Droogsma E, van Asselt DZ, van Steijn JH, Schuur T, Huinink EJ. Effect of long-term treatment with galantamine on weight of patients with Alzheimer's dementia. J Nutr Health Aging. 2013
- Corbo JM, Brown JN, Moss JM. Galantamine-associated nightmares and anxiety. Consult Pharm. 2013
- Matthews JD, Siefert CJ, Blais MA, Park LT, Siefert CJ, Welch CA, Dubois CM, van Nieuwenhuizen AO, Rooney KO, Seabrook RC, Durham LE, Adams HC, Fava M. A double-blind, placebo-controlled study of the impact of galantamine on anterograde memory impairment during electroconvulsive therapy. J ECT. 2013
- Triana-Vidal LE, Carvajal-Varona SM. Protective effect of galantamine against oxidative damage using human lymphocytes: a novel in vitro model. Arch Med Res. 2013
- Hamuro A. Combination therapy with galantamine and memantine improves behavioral and psychological symptoms of dementia (BPSD) in patients with early-onset Alzheimer's disease. Aust N Z J Psychiatry. 2013
- Simoni E, Daniele S, Bottegoni G, Pizzirani D, Trincavelli ML, Goldoni L, Tarozzo G, Reggiani A, Martini C, Piomelli D, Melchiorre C, Rosini M, Cavalli A. Combining galantamine and memantine in multitargeted, new chemical entities potentially useful in Alzheimer's disease. J Med Chem. 2012
- Sofuoglu M, Herman AI, Li Y, Waters AJ. Galantamine attenuates some of the subjective effects of intravenous nicotine and improves performance on a Go No-Go task in abstinent cigarette smokers: a preliminary report. Psychopharmacology (Berl). 2012
- Peters O, Lorenz D, Fesche A, Schmidtke K, Hüll M, Perneczky R, Rüther E, Möller HJ, Jessen F, Maier W, Kornhuber J, Jahn H, Luckhaus C, Gertz HJ, Schröder J, Pantel J, Teipel S, Wellek S, Frölich L, Heuser I. A combination of galantamine and memantine modifies cognitive function in subjects with amnestic MCI. J Nutr Health Aging. 2012
- Hong JM, Shin DH, Lim TS, Lee JS, Huh K. Galantamine administration in chronic post-stroke aphasia. J Neurol Neurosurg Psychiatry. 2012
- Bond M, Rogers G, Peters J, Anderson R, Hoyle M, Miners A, Moxham T, Davis S, Thokala P, Wailoo A, Jeffreys M, Hyde C. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model. Health Technol Assess. 2012
- Wimo A, Gaudig M, Schäuble B, Jedenius E. The economic impact of galantamine vs placebo: an analysis based on functional capacity in a Swedish cohort study. J Med Econ. 2012
- de Souza FM, Busquet N, Blatner M, Maclean KN, Restrepo D. Galantamine improves olfactory learning in the Ts65Dn mouse model of Down syndrome. Sci Rep. 2011
- Engedal K, Davis B, Richarz U, Han J, Schäuble B, Andreasen N. Two galantamine titration regimens in patients switched from donepezil. Acta Neurol Scand. 2012
- Kavanagh S, Van Baelen B, Schäuble B. Long-term effects of galantamine on cognitive function in Alzheimer's disease: a large-scale international retrospective study. J Alzheimers Dis. 2011
- Walsh R, Rockwood K, Martin E, Darvesh S. Synergistic inhibition of butyrylcholinesterase by galantamine and citalopram. Biochim Biophys Acta. 2011
- Gaudig M, Richarz U, Han J, Van Baelen B, Schäuble B. Effects of galantamine in Alzheimer's disease: double-blind withdrawal studies evaluating sustained versus interrupted treatment. Curr Alzheimer Res. 2011
- Kavanagh S, Gaudig M, Van Baelen B, Adami M, Delgado A, Guzman C, Jedenius E, Schäuble B. Galantamine and behavior in Alzheimer disease: analysis of four trials. Acta Neurol Scand. 2011
- Scarpini E, Bruno G, Zappalà G, Adami M, Richarz U, Gaudig M, Jacobs A, Schäuble B. Cessation versus continuation of galantamine treatment after 12 months of therapy in patients with Alzheimer's disease: a randomized, double blind, placebo controlled withdrawal trial. J Alzheimers Dis. 2011
- Ago Y, Koda K, Takuma K, Matsuda T. Pharmacological aspects of the acetylcholinesterase inhibitor galantamine. J Pharmacol Sci. 2011
- Sofuoglu M, Carroll KM. Effects of galantamine on cocaine use in chronic cocaine users. Am J Addict. 2011
- Sofuoglu M, Waters AJ, Poling J, Carroll KM. Galantamine improves sustained attention in chronic cocaine users. Exp Clin Psychopharmacol. 2011
- Isik AT, Bozoglu E, Naharci MI, Kilic S. Evaluation of the effects of galantamine on cardiac function in elderly patients with Alzheimer's disease. Am J Geriatr Pharmacother. 2010
- Rosenbloom MH, Brown J, Berlowitz DR, Budson AE. Safety and tolerability of galantamine SA in dementia patients transitioned from donepezil. Consult Pharm. 2011
- Kavanagh S, Howe I, Brashear HR, Wang D, van Baelen B, Todd M, Schwalen S. Long-term response to galantamine in relation to short-term efficacy data: pooled analysis in patients with mild to moderate Alzheimer's disease. Curr Alzheimer Res. 2011
- Van Puyvelde K, Mets T; RODOS Study Group. Galantamine (Reminyl) once daily outcome and satisfaction survey (RODOS) in mild to moderate Alzheimer's disease: a study in a real life population. Geriatr Gerontol Int. 2011
- Keller C, Kadir A, Forsberg A, Porras O, Nordberg A. Long-term effects of galantamine treatment on brain functional activities as measured by PET in Alzheimer's disease patients. J Alzheimers Dis. 2011
- Hernández-Fernández F, Pardal-Fernández JM, GarcÃa-MartÃnez E, Segura T. Respiratory myoclonus, a side effect of galantamine. Farm Hosp. 2011
- Guo S, Hernandez L, Wasiak R, Gaudig M. Modelling the clinical and economic implications of galantamine in the treatment of mild-to-moderate Alzheimer's disease in Germany. J Med Econ. 2010
- Takata K, Kitamura Y, Saeki M, Terada M, Kagitani S, Kitamura R, Fujikawa Y, Maelicke A, Tomimoto H, Taniguchi T, Shimohama S. Galantamine-induced amyloid-{beta} clearance mediated via stimulation of microglial nicotinic acetylcholine receptors. J Biol Chem. 2010
- Lindenmayer JP, Khan A. Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia. Schizophr Res. 2011
- Li Q, Fang J, Yang M, Wu D, Zhang L, Zhang Y. Galantamine inhibits calpain-calcineurin signaling activated by beta-amyloid in human neuroblastoma SH-SY5Y cells. Neurosci Lett. 2010
- Li Q, Wu D, Zhang L, Zhang Y. Effects of galantamine on β-amyloid release and beta-site cleaving enzyme 1 expression in differentiated human neuroblastoma SH-SY5Y cells. Exp Gerontol. 2010
- Dev H, Agius M, Zaman R. The dramatic effects of Galantamine in a patient with early-onset Alzheimer's disease. Psychiatr Danub. 2010
- Romero A, Egea J, GarcÃa AG, López MG. Synergistic neuroprotective effect of combined low concentrations of galantamine and melatonin against oxidative stress in SH-SY5Y neuroblastoma cells. J Pineal Res. 2010
- Seltzer B. Galantamine-ER for the treatment of mild-to-moderate Alzheimer's disease. Clin Interv Aging. 2010
- Huang F, Fu Y. A review of clinical pharmacokinetics and pharmacodynamics of galantamine, a reversible acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, in healthy subjects and patients. Curr Clin Pharmacol. 2010
- Prvulovic D, Hampel H, Pantel J. Galantamine for Alzheimer's disease. Expert Opin Drug Metab Toxicol. 2010
- Santoro A, Siviero P, Minicuci N, Bellavista E, Mishto M, Olivieri F, Marchegiani F, Chiamenti AM, Benussi L, Ghidoni R, Nacmias B, Bagnoli S, Ginestroni A, Scarpino O, Feraco E, Gianni W, Cruciani G, Paganelli R, Di Iorio A, Scognamiglio M, Grimaldi LM, Gabelli C, et al. Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study. CNS Drugs. 2010
- Penner J, Rupsingh R, Smith M, Wells JL, Borrie MJ, Bartha R. Increased glutamate in the hippocampus after galantamine treatment for Alzheimer disease. Prog Neuropsychopharmacol Biol Psychiatry. 2010
- Maelicke A, Hoeffle-Maas A, Ludwig J, Maus A, Samochocki M, Jordis U, Koepke AK. Memogain is a galantamine pro-drug having dramatically reduced adverse effects and enhanced efficacy. J Mol Neurosci. 2010
- Ghaemi SN, Gilmer WS, Dunn RT, Hanlon RE, Kemp DE, Bauer AD, Chriki L, Filkowski MM, Harvey PD. A double-blind, placebo-controlled pilot study of galantamine to improve cognitive dysfunction in minimally symptomatic bipolar disorder. J Clin Psychopharmacol. 2009
- Elgamal SA, Marriott M, Macqueen GM. Electroencephalographic effects of galantamine in major depressive disorder. J Clin Neurophysiol. 2009
- Matharu B, Gibson G, Parsons R, Huckerby TN, Moore SA, Cooper LJ, Millichamp R, Allsop D, Austen B. Galantamine inhibits beta-amyloid aggregation and cytotoxicity. J Neurol Sci. 2009
- Feldman HH, Pirttila T, Dartigues JF, Everitt B, Van Baelen B, Schwalen S, Kavanagh S. Treatment with galantamine and time to nursing home placement in Alzheimer's disease patients with and without cerebrovascular disease. Int J Geriatr Psychiatry. 2009
Article last updated on: July 3rd, 2018 by Nootriment